Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: Systematic review and meta-analysis of randomized and observational studies | diabetes.medicinematters.com

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

01-11-2016 | Heart failure | Review | Article

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

Please follow the link below to view this article in full on a third party website. Note that a subscription or payment may be required.

http://www.bmj.com/content/352/bmj.i610

We hope to be able to offer the full text article on Medicine Matters diabetes in the near future.

Version: 0.1948.0

Medicine Matters Diabetes

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

New additions to the Adis Journal Club

The challenge of type 2 diabetes in children

Supporting people with diabetes during Ramadan